BOSTON, August 6, 2025 — Leads & Copy — Entrada Therapeutics Inc. (Nasdaq: TRDA) reported its second-quarter financial results for the period ending June 30, 2025, alongside recent business updates. The company highlighted the dosing of the first patient in the ELEVATE-44-201 clinical study and anticipates data from the first patient cohort in H1 2026. Additionally, the ELEVATE-45-201 study has been initiated, with the first patient expected to be dosed in Q3 2025. Multiple clinical trial sites in the U.K. and EU have been activated for both studies. The company’s leadership team has expanded with the appointments of Navid Khan, PhD, as Senior Vice President of Medical Affairs, and Kiran Patki, MD, MSc, FFPM, as Senior Vice President of Clinical Development. Entrada Therapeutics expects its cash runway to extend into Q2 2027, supported by $354 million in cash, cash equivalents, and marketable securities as of June 30, 2025.
Dipal Doshi, CEO of Entrada Therapeutics, noted the critical need for safer, more effective therapeutic options for Duchenne muscular dystrophy (DMD) patients.
Key progress includes advancing multiple clinical programs for DMD patients in the U.K., EU, and U.S. The ELEVATE-44-201 study has dosed its first patient and expects to report data from Cohort 1 in the first half of 2026. The ELEVATE-45-201 study is on track to dose its first patient in the third quarter of 2025, with data from Cohort 1 expected in mid-2026.
Entrada also anticipates submitting global regulatory applications for ENTR-601-50 in Q4 2025 and for ENTR-601-51 in 2026. Vertex continues to enroll patients in the Phase 1/2 clinical trial of VX-670 for myotonic dystrophy type 1 (DM1), with completion expected in the first half of 2026.
The company has also made strides in its preclinical pipeline, advancing two inherited retinal disease programs into lead optimization, with a clinical candidate nomination expected by the end of 2025.
Karla MacDonald, Chief Corporate Affairs Officer, kmacdonald@entradatx.com
Sarah Friedhoff, Head of Patient Advocacy, patientadvocacy@entradatx.com
Megan Prock McGrath, CTD Comms, LLC, megan@ctdcomms.com
Source: Entrada Therapeutics
